Previous Article | Next Article 
Antimicrob Agents Chemother. 1991 March; 35(3): 490-496
Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.
T Iwahi,
H Satoh,
M Nakao,
T Iwasaki,
T Yamazaki,
K Kubo,
T Tamura and
A Imada
Research and Development Division, Takeda Chemical Industries, Ltd., Osaka, Japan.
ABSTRACT
The activities of various types of antiulcer agents against Helicobacter pylori (formerly called Campylobacter pylori) strains were determined by an agar dilution method. Among the compounds tested, two benzimidazole proton pump inhibitors, lansoprazole (AG-1749) and omeprazole, were found to have significant activities against this organism. The activity of lansoprazole was comparable to that of bismuth citrate, with MICs ranging from 3.13 to 12.5 micrograms/ml, and fourfold more potent than that of omeprazole. A major metabolite and two acid-converted rearrangement products of lansoprazole also exhibited good activities comparable or superior to that of the parent compound. Exposure to lansoprazole of H. pylori growing in a liquid medium led to an extensive loss of viability without a reduction in culture turbidity and produced an aberrant bacterial morphology characterized by the irregular constriction of cells and the collapse of cell surface structures. The antibacterial activity of lansoprazole and its related compounds was selective against H. pylori; common aerobic and anaerobic bacteria and Campylobacter jejuni were not inhibited by 100 micrograms/ml.
Antimicrob Agents Chemother. 1991 March; 35(3): 490-496
This article has been cited by other articles:
-
Yeo, M, Kim, D-K, Han, S U, Lee, J E, Kim, Y B, Cho, Y K, Kim, J H, Cho, S W, Hahm, K-B
(2006). Novel action of gastric proton pump inhibitor on suppression of Helicobacter pylori induced angiogenesis. Gut
55: 26-33
[Abstract]
[Full Text]
-
Sutak, R., Tachezy, J., Kulda, J., Hrdy, I.
(2004). Pyruvate Decarboxylase, the Target for Omeprazole in Metronidazole-Resistant and Iron-Restricted Tritrichomonas foetus. Antimicrob. Agents Chemother.
48: 2185-2189
[Abstract]
[Full Text]
-
Afeltra, J., Vitale, R. G., Mouton, J. W., Verweij, P. E.
(2004). Potent Synergistic In Vitro Interaction between Nonantimicrobial Membrane-Active Compounds and Itraconazole against Clinical Isolates of Aspergillus fumigatus Resistant to Itraconazole. Antimicrob. Agents Chemother.
48: 1335-1343
[Abstract]
[Full Text]
-
Nagata, K., Sone, N., Tamura, T.
(2001). Inhibitory Activities of Lansoprazole against Respiration in Helicobacter pylori. Antimicrob. Agents Chemother.
45: 1522-1527
[Abstract]
[Full Text]
-
Tsutsui, N., Taneike, I., Ohara, T., Goshi, S., Kojio, S., Iwakura, N., Matsumaru, H., Wakisaka-Saito, N., Zhang, H.-M., Yamamoto, T.
(2000). A Novel Action of the Proton Pump Inhibitor Rabeprazole and Its Thioether Derivative against the Motility of Helicobacter pylori. Antimicrob. Agents Chemother.
44: 3069-3073
[Abstract]
[Full Text]
-
TAKAHASHI, M., TAGUCHI, H., YAMAGUCHI, H., OSAKI, T., KAMIYA, S.
(2000). Studies of the effect of Clostridium butyricum on Helicobacter pylori in several test models including gnotobiotic mice. J Med Microbiol
49: 635-642
[Abstract]
[Full Text]
-
Salcedo, J. A., Al-Kawas, F.
(1998). Treatment of Helicobacter pylori Infection. Arch Intern Med
158: 842-851
[Abstract]
[Full Text]
-
Walsh, J. H., Peterson, W. L.
(1995). The Treatment of Helicobacter pylori Infection in the Management of Peptic Ulcer Disease. NEJM
333: 984-991
[Full Text]
-
Graham, D. Y.
(1993). Treatment of Peptic Ulcers Caused by Helicobacter pylori. NEJM
328: 349-350
[Full Text]
Copyright © 1991 by the American Society for Microbiology. All rights reserved.